OBJECTIVE: To determine whether methadone, buprenorphine, or detoxification treatment is the most cost-effective approach to the management of opioid use disorder (OUD) during pregnancy. STUDY DESIGN: A decision analytic model compared the cost-effectiveness of initiation of methadone, buprenorphine, or detoxification in treating OUD during pregnancy. Women were assumed to be appropriate candidates for all three treatment strategies. Probabilities, costs, and utilities were determined from the existing literature. Incremental cost-effective ratios (ICERs) for each strategy were calculated and an ICER of $100,000/QALY was used to define cost effectiveness. One-way sensitivity analyses and a Monte Carlo probabilistic sensitivity analysis were performed. RESULTS: Using baseline estimates, initiation of buprenorphine was more effective at a lower cost than either methadone or detoxification; thus, detoxification was dominated by both methadone and buprenorphine (Table) . Based on a nationwide estimate of 20,000 pregnant women affected by OUD annually, buprenorphine use led to a cost savings of 179 million dollars when compared to methadone and 1.49 billion dollars when compared to detoxification. In one-way sensitivity analyses, methadone became the most costeffective strategy when the medication cost of buprenorphine exceeded 337 dollars/month (169% of the base case estimate) or if the incidence of relapse among women on buprenorphine was higher than 35% (422% of the base case estimate). Monte Carlo analyses revealed that buprenorphine was always cost-effective compared with the other strategies and dominated the other strategies 99.7% of the time. CONCLUSION: Buprenorphine is more cost-effective than either methadone or detoxification as treatment for OUD during pregnancy when all treatment options are medically appropriate. This finding was robust in sensitivity analyses.
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